The multivariate stratified analysis revealed no increased risk of liver injury across all examined subgroups, including the presence or absence of liver cirrhosis, viral hepatitis, chronic hepatitis, subsequent ESRD, or each OHAs use, including metformin, DPP4-inhibitors, thiazolidinedione, or sulfonylurea (Fig. 2). Here, DPP4 is linked to chronic hepatitis.